LONDON, UNITED KINGDOM, May 30, 2018 (GLOBE NEWSWIRE) — Plandai Biotechnology, Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly phyto-available extracts, is pleased to report positive results from chicken studies on how Phytofare® infused SORBEO™ is beneficial as a feed additive in poultry diets.
The commercial studies demonstrated on average a 7% increase in weight at a lower mortality rate for the chicks. Extrapolating the data from the experiment and projecting it to what the potential effect could be for a broiler farm indicates that over a period of one year the profit per chick can be increased by up to 18%. This equates to increased profitability for the producer as the chicks reach weight faster, and on less feed, while also having more birds reach maturity. Earlier studies showed that there was no change in taste, color or appearance in the meat of birds fed a diet supplemented by Phytofare®–a true win-win for the poultry industry.
SORBEO™ proprietary PREMIX is an affordable and cost-effect formulation that is recovered from live green tea leaf and consists of a proprietary complex of all eight catechins, caffeine, amino acids, minerals and other phytonutrients.
Red Gold Biotechnologies (Pty) Limited, Deltamune (Pty) Limited, and LabServe, have undertaken ethics-approved clinical pen and commercial studies to determine the wellness benefits of improved gut maintenance to the poultry industry provided by the use of Phytofare® in the SORBEO™ proprietary PREMIX. The studies examined the benefits of Phytofare® when delivered in a low dosage formulated in liposome iotas, then added to feed formulations which were fed to the control groups of chickens. Four scientifically documented studies independently validated that Phytofare® catechins were transferred to and remained in the chicken plasma for more than 24 hours.
These overall pen study findings have established that Phytofare® formulated in Liposome Iotas and mixed with chicken feed, delivers a notable benefit to the growth performance of broilers. Commercialization of SORBEO™ proprietary Phytofare® premix commenced in October 2017 in new studies at Mikon Farming Sidwale Caves, Mpumalanga South Africa, with control and Phytofare® poultry houses each containing flocks of 14,000 birds.
The findings showed that the Phytofare® group had an overall weight increase with lower mortality levels and improved co-efficiency ratios when measured against the control group. The treated group weighed on average 7% more at the time of slaughter than the control group. The difference between the treated group and the control group were noticeable from week 1 (2%) and slowly increased to 7% at slaughter. At the same time the weight-coefficient variance percentage (CV%) of the treated group was 10% lower than the control group. The difference in CV% between the treated group and control was evident as well from the first week and the difference increased over time as well. Feed intake for the treated group was only 3% higher than the control group although the weight advantage was at 7%.
Extrapolating data from the experiment and projecting it to what the potential effect could be for a broiler farm has indicated that over a period of a year the profit per bird space can be increased by up to 18% over current values. This was based on the fact that with earlier slaughter by two days per cycle an additional cycle could be fitted in every 15th cycle while also having lower feed costs per bird. That value was multiplied by the improved performance of the treated group over the control group. Add to that the anti-microbial effects of SORBEO™ PREMIX on pathogenic bacteria and it is likely that mortality rates will decrease as well leading to further improved profits. With increasing pressure from the World Health Organization, consumers, food processors and retailers to eliminate antibiotics from the feed of the broilers, SORBEO™ PREMIX can make this huge difference. If the performance is even better, and results in slaughter three or four days earlier, the effect on profit is even more dramatic.
The beneficial effects of green tea catechins have been studied in poultry and are well documented; however, the bioavailability of green tea extracts is extremely low due to poor absorption and retention after passing through the stomach and gizzard. Furthermore, the poor bioavailability of all other green tea extracts has restricted the commercialization of using catechins as a feed supplement, with further difficulties airing from the otherwise high dosage levels that would be required to achieve a clinical effect also impacting taste to the consumer.
SORBEO™ PREMIX, however, which is recovered from live green tea leaf and pellet formulated into the diet of poultry, has overcome these challenges and delivers an improved gut maintenance program that has demonstrated stronger and healthier birds. This includes the efficient delivery throughout the life cycle of the chicken with a low milligram dosage of the protected catechin complex that supports efficient transfer and protection of the antioxidants through both the chicken’s stomach and gizzard, followed by the subsequent release and retention of the catechins in the plasma for more than 24 hours.
About Plandai Biotechnology, Inc.
Plandai Biotechnology, Inc. (OTC Markets: PLPL) develops highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare® extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. The manufacturing facility has also been engineered for citrus fruits and the recovery of limonoids. Targeted industries for the Company’s products include animal husbandry, dietary supplements, diabetes and cannabis. Plandai Biotechnology is headquartered in London, United Kingdom. For more information, please visit: http://www.plandaibiotech.com
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company’s filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.